Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts

Anna V. Naumova, Vadappuram P. Chacko, Ronald Ouwerkerk, Linda Stull, Eduardo Marbán, Robert George Weiss

Research output: Contribution to journalArticle

Abstract

After myocardial infarction, ventricular geometry and function, as well as energy metabolism, change markedly. In nonischemic heart failure, inhibition of xanthine oxidase (XO) improves mechanoenergetic coupling by improving contractile performance relative to a reduced energetic demand. However, the metabolic and contractile effects of XO inhibitors (XOIs) have not been characterized in failing hearts after infarction. After undergoing permanent coronary ligation, mice received a XOI (allopurinol or oxypurinol) or matching placebo in the daily drinking water. Four weeks later, 1H MRI and 31P magnetic resonance spectroscopy (MRS) were used to quantify in vivo functional and metabolic changes in postinfarction remodeled mouse myocardium and the effects of XOIs on that process. End-systolic (ESV) and end-diastolic volumes (EDV) were increased by more than sixfold after infarction, left ventricle (LV) mass doubled (P <0.005), and the LV ejection fraction (EF) decreased (14 ± 9%) compared with control hearts (59 ± 8%, P <0.005) at 1 mo. The myocardial phosphocreatine (PCr)-to-ATP ratio (PCr/ATP) was also significantly decreased in infarct remodeled hearts (1.4 ± 0.6) compared with control animals (2.1 ± 0.5, P <0.02), in agreement with prior studies in larger animals. The XOIs allopurinol and oxypurinol did not change LV mass but limited the increase in ESV and EDV of infarct hearts by 50%, increased EF (23 ± 9%, P = 0.01), and normalized cardiac PCr/ATP (2.0 ± 0.5, P <0.04). We conclude that XOIs improve ventricular function after infarction and normalize high-energy phosphate ratio in heart failure. Thus XOI therapy offers a new and potentially complementary approach to limit the adverse contractile and metabolic consequences after infarction.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume290
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Xanthine Oxidase
Infarction
Phosphocreatine
Oxypurinol
Heart Ventricles
Allopurinol
Ventricular Function
Adenosine Triphosphate
Heart Failure
Cardiac Volume
Drinking Water
Energy Metabolism
Ligation
Myocardium
Magnetic Resonance Spectroscopy
Phosphates
Myocardial Infarction
Placebos
Therapeutics

Keywords

  • Allopurinol
  • Cardiac metabolism
  • Magnetic resonance spectroscopy
  • Postinfarction remodeled myocardium

ASJC Scopus subject areas

  • Physiology

Cite this

Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. / Naumova, Anna V.; Chacko, Vadappuram P.; Ouwerkerk, Ronald; Stull, Linda; Marbán, Eduardo; Weiss, Robert George.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 290, No. 2, 02.2006.

Research output: Contribution to journalArticle

Naumova, Anna V. ; Chacko, Vadappuram P. ; Ouwerkerk, Ronald ; Stull, Linda ; Marbán, Eduardo ; Weiss, Robert George. / Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. In: American Journal of Physiology - Heart and Circulatory Physiology. 2006 ; Vol. 290, No. 2.
@article{b1fb280cf8e2462299c67088e0c077dd,
title = "Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts",
abstract = "After myocardial infarction, ventricular geometry and function, as well as energy metabolism, change markedly. In nonischemic heart failure, inhibition of xanthine oxidase (XO) improves mechanoenergetic coupling by improving contractile performance relative to a reduced energetic demand. However, the metabolic and contractile effects of XO inhibitors (XOIs) have not been characterized in failing hearts after infarction. After undergoing permanent coronary ligation, mice received a XOI (allopurinol or oxypurinol) or matching placebo in the daily drinking water. Four weeks later, 1H MRI and 31P magnetic resonance spectroscopy (MRS) were used to quantify in vivo functional and metabolic changes in postinfarction remodeled mouse myocardium and the effects of XOIs on that process. End-systolic (ESV) and end-diastolic volumes (EDV) were increased by more than sixfold after infarction, left ventricle (LV) mass doubled (P <0.005), and the LV ejection fraction (EF) decreased (14 ± 9{\%}) compared with control hearts (59 ± 8{\%}, P <0.005) at 1 mo. The myocardial phosphocreatine (PCr)-to-ATP ratio (PCr/ATP) was also significantly decreased in infarct remodeled hearts (1.4 ± 0.6) compared with control animals (2.1 ± 0.5, P <0.02), in agreement with prior studies in larger animals. The XOIs allopurinol and oxypurinol did not change LV mass but limited the increase in ESV and EDV of infarct hearts by 50{\%}, increased EF (23 ± 9{\%}, P = 0.01), and normalized cardiac PCr/ATP (2.0 ± 0.5, P <0.04). We conclude that XOIs improve ventricular function after infarction and normalize high-energy phosphate ratio in heart failure. Thus XOI therapy offers a new and potentially complementary approach to limit the adverse contractile and metabolic consequences after infarction.",
keywords = "Allopurinol, Cardiac metabolism, Magnetic resonance spectroscopy, Postinfarction remodeled myocardium",
author = "Naumova, {Anna V.} and Chacko, {Vadappuram P.} and Ronald Ouwerkerk and Linda Stull and Eduardo Marb{\'a}n and Weiss, {Robert George}",
year = "2006",
month = "2",
doi = "10.1152/ajpheart.00831.2005",
language = "English (US)",
volume = "290",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts

AU - Naumova, Anna V.

AU - Chacko, Vadappuram P.

AU - Ouwerkerk, Ronald

AU - Stull, Linda

AU - Marbán, Eduardo

AU - Weiss, Robert George

PY - 2006/2

Y1 - 2006/2

N2 - After myocardial infarction, ventricular geometry and function, as well as energy metabolism, change markedly. In nonischemic heart failure, inhibition of xanthine oxidase (XO) improves mechanoenergetic coupling by improving contractile performance relative to a reduced energetic demand. However, the metabolic and contractile effects of XO inhibitors (XOIs) have not been characterized in failing hearts after infarction. After undergoing permanent coronary ligation, mice received a XOI (allopurinol or oxypurinol) or matching placebo in the daily drinking water. Four weeks later, 1H MRI and 31P magnetic resonance spectroscopy (MRS) were used to quantify in vivo functional and metabolic changes in postinfarction remodeled mouse myocardium and the effects of XOIs on that process. End-systolic (ESV) and end-diastolic volumes (EDV) were increased by more than sixfold after infarction, left ventricle (LV) mass doubled (P <0.005), and the LV ejection fraction (EF) decreased (14 ± 9%) compared with control hearts (59 ± 8%, P <0.005) at 1 mo. The myocardial phosphocreatine (PCr)-to-ATP ratio (PCr/ATP) was also significantly decreased in infarct remodeled hearts (1.4 ± 0.6) compared with control animals (2.1 ± 0.5, P <0.02), in agreement with prior studies in larger animals. The XOIs allopurinol and oxypurinol did not change LV mass but limited the increase in ESV and EDV of infarct hearts by 50%, increased EF (23 ± 9%, P = 0.01), and normalized cardiac PCr/ATP (2.0 ± 0.5, P <0.04). We conclude that XOIs improve ventricular function after infarction and normalize high-energy phosphate ratio in heart failure. Thus XOI therapy offers a new and potentially complementary approach to limit the adverse contractile and metabolic consequences after infarction.

AB - After myocardial infarction, ventricular geometry and function, as well as energy metabolism, change markedly. In nonischemic heart failure, inhibition of xanthine oxidase (XO) improves mechanoenergetic coupling by improving contractile performance relative to a reduced energetic demand. However, the metabolic and contractile effects of XO inhibitors (XOIs) have not been characterized in failing hearts after infarction. After undergoing permanent coronary ligation, mice received a XOI (allopurinol or oxypurinol) or matching placebo in the daily drinking water. Four weeks later, 1H MRI and 31P magnetic resonance spectroscopy (MRS) were used to quantify in vivo functional and metabolic changes in postinfarction remodeled mouse myocardium and the effects of XOIs on that process. End-systolic (ESV) and end-diastolic volumes (EDV) were increased by more than sixfold after infarction, left ventricle (LV) mass doubled (P <0.005), and the LV ejection fraction (EF) decreased (14 ± 9%) compared with control hearts (59 ± 8%, P <0.005) at 1 mo. The myocardial phosphocreatine (PCr)-to-ATP ratio (PCr/ATP) was also significantly decreased in infarct remodeled hearts (1.4 ± 0.6) compared with control animals (2.1 ± 0.5, P <0.02), in agreement with prior studies in larger animals. The XOIs allopurinol and oxypurinol did not change LV mass but limited the increase in ESV and EDV of infarct hearts by 50%, increased EF (23 ± 9%, P = 0.01), and normalized cardiac PCr/ATP (2.0 ± 0.5, P <0.04). We conclude that XOIs improve ventricular function after infarction and normalize high-energy phosphate ratio in heart failure. Thus XOI therapy offers a new and potentially complementary approach to limit the adverse contractile and metabolic consequences after infarction.

KW - Allopurinol

KW - Cardiac metabolism

KW - Magnetic resonance spectroscopy

KW - Postinfarction remodeled myocardium

UR - http://www.scopus.com/inward/record.url?scp=33644619835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644619835&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00831.2005

DO - 10.1152/ajpheart.00831.2005

M3 - Article

VL - 290

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 2

ER -